Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study

Circulation Journal

Volumn 69, Issue 8, 2005, Pages 875-883

  Yokoi, Hiroyoshi ^a   Nobuyoshi, Masakiyo ^a   Mitsudo, Kazuaki ^a,b   Kawaguchi, Akito ^a,c   Yamamoto, Akira ^a,c  

^a KOKURA MEMORIAL HOSPITAL   (Japan)

^b KURASHIKI CENTRAL HOSPITAL   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Cholesterol lowering trial; Pravastatin; Quantitative coronary angiography; Randomized controlled clinical trial; Regression

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; DRUG ERUPTION; ETHNIC GROUP; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; HYPOPHAGIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NEOPLASM; RANDOMIZED CONTROLLED TRIAL;

CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; FOLLOW-UP STUDIES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PRAVASTATIN;

EID: 23744504398     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.69.875     Document Type: Article

References (47)

1. Menotti A, Blackburn H, Kromhout D, Nissinen A, Fidanza F, Giampaoli S, et al. Changes in population cholesterol levels and coronary heart disease deaths in seven countries. Eur Heart J 1997; 18: 566-571.
2. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583-612.
3. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: Twenty-five year follow-up of the seven countries study. JAMA 1995; 274: 131-136.
4. Yamamoto A, Temba H, Horibe H, Mabuchi H, Saito Y, Matsuzawa Y, et al. Life style and cardiovascular risk factors in the Japanese population - from an epidemiological survey on serum lipid levels in Japan 1990 part 2: Association of lipid parameters with hypertension. J Atheroscler Thromb 2003; 10: 176-185.
5. Yamamoto A, Richie G, Nakamura H, Hosoda S, Nobuyoshi M, Matsuzaki M, et al. Risk factors for coronary heart disease in the Japanese - comparison of the background of patients with acute coronary syndrome in the ASPAC study with data obtained from the general population: Asia-Pacific Collaboration on CHD Risk Factor Intervention study. J Atheroscler Thromb 2002; 9: 191-199.
6. Konishi M, Iso H, Iida M, Naito Y, Sato S, Komachi Y, et al. Trends for coronary heart disease and its risk factors in Japan: Epidemiologic and pathologic studies. Jpn Circ J 1990; 54: 428-435.
7. Kodama K, Sasaki H, Shimizu Y. Trend of coronary heart disease and its relationship to risk factors in a Japanese population: A 26-year follow-up, Hiroshima/Nagasaki study. Jpn Circ J 1990; 54: 414-421.
8. Okamura T, Kadowaki T, Hayakawa T, Kita Y, Okayama A, Ueshima H. What cause of mortality can we predict by cholesterol screening in the Japanese general population? J Intern Med 2003; 253: 169-180.
9. Takeuchi H, Saitoh S, Takagi A, Onishi H, Ohata J, Isobe T, et al. Changes in the incidence of acute myocardial infarction in Obihiro City, Hokkaido, Japan, compared with 10 years ago. Jpn J Cardiovasc Dis Prev 2002; 37: 181-185.
10. Wakugami K, Iseki K, Kimura Y, Okumura K, Ikemiya Y, Muratani H, et al. Relationship between serum cholesterol and the risk of acute myocardial infarction in a screened cohort in Okinawa, Japan. Jpn Circ J 1998; 62: 7-14.
11. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
13. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, et al. Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS): The MARS Research Group. Ann Intern Med 1993; 119: 969-976.
14. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89: 959-968.
15. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-2540.
16. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events: PLAC I investigation. J Am Coll Cardiol 1995; 26: 1133-1139.
17. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ 3rd, Jones PH, West MS, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278-286.
18. MAAS investigators. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633-638.
19. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-1791.
20. Yamamoto A, Temba H, Horibe H, Mabuchi H, Saito Y, Matsuzawa Y, et al. Life style and cardiovascular risk factors in the Japanese population - from an epidemiological survey on serum lipid levels in Japan 1990 part 1: Influence of life style and excess body weight on HDL-cholesterol and other lipid parameters in men. J Atheroscler Thromb 2003; 10: 165-175.
21. Iwasaki M, Otani T, Yamamoto S, Inoue M, Hanaoka T, Sobue T, et al. Background characteristics of basic health examination participants: The JPHC Study Baseline Survey. J Epidemiol 2003; 13: 216-225.
22. Tanaka H, Date C, Chen H, Nakayama T, Yokoyama T, Yoshiike N, et al. A brief review of epidemiological studies on ischemic heart disease in Japan. J Epidemiol 1996; 6(Suppl 3): S49-S59.
23. Tachibana E, Watanabe I, Nagao K, Kanmatsuse K. Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients. J Cardiol 2000; 35: 277-285.
24. Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 2002; 66: 1087-1095.
25. Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: Secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002; 66: 1096-1100.
26. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J 2004; 68: 860-867.
27. Tamura A, Mikuriya Y, Nasu M. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease: Coronary Artery Regression Study (CARS) Group. Am J Cardiol 1997; 79: 893-896.
28. Yui Y, Shinoda E, Hattori R, Morishita H, Hosada S, Kawai C. Preventive effect of pravastatin on progression of coronary artery stenosis: Assessment with quantitative coronary arteriography (caliper method). Shinzo 2001; 33: 15-24.
29. Nakagawa T, Kobayashi T, Awata N, Sato S, Reiber JHC, Nakajima H, et al. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: Final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study. Int J Cardiol 2004; 97: 107-114.
30. Kawaguchi A, Mitsudo K, Nobuyoshi M, Minamino R, Hayasaki K, Nakashima M, et al. Angiographic intervention trial using HMG CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma in West Japan (ATHEROMA study): Rationale, design and baseline. J Cardiovasc Risk 2002; 9: 7-16.
31. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, et al. A reporting system on patients evaluated for coronary artery disease: Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51(Suppl 4): 5-40.
32. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-3023.
33. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
34. Haase J, Escaned J, van Swijndregt EM, Ozaki Y, Gronenschild E, Slager CJ, et al. Experimental validation of geometric and densitometric coronary measurements on the new generation Cardiovascular Angiography Analysis System (CAAS II). Cathet Cardiovasc Diagn 1993; 30: 104-114.
35. Gronenschild E, Janssen J, Tijdens F. CAAS. II: A second generation system for off-line and on-line quantitative coronary angiography. Cathet Cardiovasc Diagn 1994; 33: 61-75.
36. Waters D, Lesperance J, Craven TE, Hudon G, Gillam LD. Advantages and limitations of serial coronary arteriography for the assessment of progression and regression of coronary atherosclerosis: Implications for clinical trials. Circulation 1993; 87(Suppl 3): II-38-II-47.
37. Machin D, Campbell MJ, Fayers P, Pinol APY. Comparing independent groups for binary, ordered categorical and continuous data. In: Sample size tables for clinical studies, 2nd edn. Oxford: Blackwell Science Publication; 1997; 18-39.
38. Kong SX, Crawford SY, Gandhi SK, Seeger JD, Schumock GT, Lam NP, et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: A meta-analysis of clinical trials. Clin Ther 1997; 19: 778-797.
39. Ballantyne CM, Herd JA, Dunn JK, Jones PH, Farmer JA, Gotto AM Jr. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol 1997; 8: 354-361.
40. Matsuzawa Y, Kita T, Mabuchi H, Matsuzaki M, Nakaya N, Oikawa S, et al; J-LIT Study Group. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J 2003; 67: 287-294.
41. Sasaki J, Arakawa K, Iwashita M, Matsushita Y, Kono S; Kyushu Lipid Intervention Study (KLIS) Group. Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men: The Kyushu Lipid Intervention Study. Circ J 2003; 67: 473-478.
42. Iwashita M, Matsushita Y, Sasaki J, Arakawa K, Kono S; Kyushu Lipid Intervention Study (KLIS) Group. Relation of serum total cholesterol and other risk factors to risk of coronary events in middle-aged and elderly Japanese men with hypercholesterolemia: The Kyushu Lipid Intervention Study. Circ J 2004; 68: 405-409.
43. Saito Y, Goto Y, Nakayama N, Hata Y, Homma Y, Naito C, et al. Clinical study of CS-514 on hyperlipidemia-Dose finding study using double-blind three-groups comparative study. J Clin Ther Med 1987; 3: 1445-1472.
44. Ryu T, Matsuzaki T, Yamanaka T, Kainuma A, Kamei S, Kabuki K, et al. The results of a 3-year clinical trial of pravastatin. J Atheroscler Thromb 1996; 24: 61-73.
45. Reiber J, Schiemanck L, van der Zwet P, Goedhart B, Koning G, Lammertsma A, et al. State of the art in quantitative coronary arteriography as of 1996. In: Reiber JHC, van der Wall EE, editors. Cardiovascular imaging. Dordrecht: Kluwer Academic; 1996; 39-56.
46. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-1298.
47. Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-569.